AIDS Cure Trials: Hopeful Drug Results from Africa | El País

Every 90 seconds, someone in the world contracts HIV. For decades, this statistic has remained stubbornly consistent, a testament to the virus’s resilience and the challenges of prevention. But a new era is dawning. Recent trials in Africa demonstrate the potential of long-acting injectable cabotegravir – a six-month preventative shot – to dramatically alter this … Read more

Gilead’s $1.7B Ouro Buy: Immune System Reset Potential

Gilead Sciences Expands Autoimmune Disease Portfolio with $1.7 Billion Ouro Medicines Acquisition In a significant move to bolster its presence in the rapidly evolving field of autoimmune disease treatment, Gilead Sciences has announced the acquisition of Ouro Medicines, a privately held biotechnology company pioneering novel T cell engager therapies. The deal, valued at $1.7 billion, … Read more